**Supplemental Table 1. Use of Thrombolytics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristic** | **Thrombolytic Use (n=177)** | **No Thrombolytic Use (n=88)** | **P value** |
| *Comfort level* | | | |
| Cardiac arrest secondary to known pulmonary embolism  Not at all comfortable  Somewhat uncomfortable  Somewhat comfortable  Very comfortable | 1 (0.6)  2 (1.1)  26 (14.8)  147 (83.5) | 7 (8)  9 (10.2)  24 (27.3)  48 (54.6) | <0.01 |
| Cardiac arrest secondary to suspected thromboembolic event  Not at all comfortable  Somewhat uncomfortable  Somewhat comfortable  Very comfortable | 2 (1.1)  19 (10.8)  87 (49.4)  68 (38.6) | 12 (13.6)  23 (26.1)  39 (44.3)  14 (15.9) | <0.01 |
| Massive pulmonary embolism  Not at all comfortable  Somewhat uncomfortable  Somewhat comfortable  Very comfortable | 2 (1.1)  4 (2.3)  26 (14.9)  143 (81.7) | 4 (4.6)  4 (4.6)  23 (26.1)  57 (64.8) | 0.01 |
| *Local Practices* | | | |
| Policy or guideline pertaining to thrombolytic use in cardiac arrest, n (%) | 49 (27.8) | 12 (13.6) | <0.01 |
| Pulmonary Embolism Response Team, n (%)  Team in place  Team being developed | 43 (24.4)  25 (14.2) | 14 (15.9)  3 (3.4) | <0.01 |
| Formulary thrombolytic, n (%)  Alteplase  Streptokinase  Tenecteplase  Reteplase | 174 (98.3)  13 (7.3)  49 (27.7)  11 (6.2) | 85 (96.6)  11 (12.5)  10 (11.4)  8 (9.1) | 0.38  0.17  <0.01  0.39 |
| Locations for thrombolytic storage\*, n (%)  Emergency department automated dispensing cabinet  Intensive care unit automated dispensing cabinet  Central pharmacy  Pharmacy satellite  Unknown | 74 (41.8)  50 (28.3)  149 (84.2)  39 (22)  13 (7.3) | 24 (27.3)  12 (13.6)  64 (72.7)  12 (13.6)  23 (26.1) | 0.02  <0.01  0.03  0.14  <0.01 |
| Thrombolytic preparation location, n (%)  At the bedside by a nurse only  At the bedside by a pharmacist only  At the bedside by either a nurse or a pharmacist  In the central pharmacy  In a pharmacy satellite | 22 (12.4)  19 (10.7)  50 (28.3)  73 (41.2)  9 (5.1) | 12 (14.3)  7 (8.3)  15 (17.9)  37 (44.1)  6 (7.1) | 0.18 |
| Thrombolytic dosing, n (%)  Alteplase 100 mg IV over 2 hours  Alteplase ≥50 kg: 50 mg; <50 kg, 0.5 mg/kg; 10 mg IV bolus over 1 minute then remaining dose over 2 hours  Alteplase 10 mg IV bolus over 1 minute then 90 mg over 2 hours  Alteplase 50 mg IV bolus over 2 minutes; may repeat in 10-30 minutes if no return of spontaneous circulation  Tenecteplase dose 30 to 50 mg IV bolus, depending on weight category  Alteplase 100 mg IVP over 2 minutes  Other | 17 (9.8)  15 (8.6)  15 (8.6)  65 (37.4)  40 (23)  12 (6.9)  10 (5.7) | 12 (14.8)  5 (6.2)  8 (9.9)  18 (22.2)  11 (13.6)  2 (2.5)  25 (30.9) | <0.01 |
| Anticoagulation initiation, n (%)  Before and following thrombolytic therapy  Concomitantly (<5 minutes)  Immediately (5 minutes – 1 hour) after thrombolytic therapy  1 to <6 hours after thrombolytic therapy  ≥6 to 24 hours after thrombolytic therapy  After aPTT or anti-Xa level results are within or below target range (regardless of time since thrombolytic dose) | 35 (19.8)  6 (3.4)  29 (16.4)  31 (17.5)  22 (12.4)  36 (20.3) | 14 (16.1)  3 (3.5)  17 (19.5)  10 (11.5)  18 (20.7)  14 (16.1) | 0.58 |
| *Barrier to Using Thrombolytics, n (%)* | | | |
| I have no barriers | 90 (50.9) | 35 (39.8) | 0.09 |
| Lack of comfort | 15 (8.5) | 13 (14.8) | 0.12 |
| Inadequate staff education | 19 (10.7) | 12 (13.6) | 0.49 |
| High cost of therapy | 11 (6.2) | 6 (6.8) | 0.85 |
| Formulary restrictions | 1 (0.6) | 2 (2.3) | 0.22 |
| Lack of evidence supporting use | 25 (14.1) | 24 (27.3) | 0.01 |
| Adverse outcomes outweigh benefit | 21 (11.9) | 20 (22.7) | 0.03 |
| Unknown patient history | 53 (29.9) | 28 (31.8) | 0.76 |

\*May add up to >100% as multiple responses were permitted